Kaj je ARE NO DATA v Slovenščini - Slovenski prevod

• ni podatkov
• podatkov
• podatki

Primeri uporabe Are no data v Angleški in njihovi prevodi v Slovenski

If there are no data.
Če teh podatkov ni.

There are no data on the use of ceftriaxone in pregnant women.
Na voljo ni nobenih podatkov o uporabi ceftriaksona pri nosečnicah.

Tasmar should not be used in children as there are no data available.
Otroci: zdravila Tasmar pri otrocih ne uporabljamo, saj podatkov ni na voljo.

There are no data for patients with Child-Pugh C(severe) hepatic impairment.
Na voljo ni podatkov za bolnike s Child-Pugh C(hudo) okvaro jeter.

NS5A RAVs: No genotype 2 infected patients experienced relapse in the clinical study and therefore there are no data regarding NS5A RAVs at the time of failure.
RAV NS5A: V klinični študiji ni noben bolnik, okužen z genotipom 2, doživel relapsa, zato ni podatkov o RAV NS5A v času neuspeha.

(See section 5.2.) There are no data in children and adolescents with renal insufficiency.
Podatkov o otrocih in mladostnikih z ledvično odpovedjo ni.

Data in patients with severe renal impairment(creatinine clearance< 30 mL/min) are limited and there are no data for patients on dialysis.
Podatki o bolnikih s hudo ledvično okvaro(očistek kreatinina< 30 ml/min) so omejeni in na voljo ni podatkov o bolnikih na dializi.

There are no data regarding the level of noninvoiced water due to lack of meters.
Zaradi pomanjkanja vodomerov ni podatka o stopnji nezaračunane vode.

With the exception of a negative in vivo rat micronucleus test, there are no data available on the effects of the combination of abacavir and lamivudine in animals.
Z izjemo negativnega mikronukleus testa, izvedenega in vivo na podganah, drugi podatki o učinkih kombinacije abakavir in lamivudin pri živalih niso na voljo.

There are no data to support the co-administration of OLYSIO and telaprevir or boceprevir.
Podatkov, ki bi podprli sočasno uporabo zdravila OLYSIO s telaprevirjem ali boceprevirjem.

Do not give this medicine to children and adolescents under 18 years of age because there are no data that show that this medicine is safe and works in this age group.
Tega zdravila ne dajajte otrokom in mladostnikom, starim manj kot 18 let, saj ni podatkov o varnosti in učinkovanju zdravila pri tej starostni skupini.

There are no data regarding the efficacy of Panretin gel when applied to complicated lesions(e. g., when lymphoedema is present).
Ni podatkov oučinkovitosti Panretin gela pri nanosu na komplicirane lezije(npr. v prisotnosti limfedema).

Renal or hepatic impairment and liver fibrosis There are no data available on the use of deferiprone in patients with renal or hepatic impairment.
Bolniki z motnjami v delovanju jeter oziroma ledvic in fibrozo jeter O uporabi deferiprona pri bolnikih z oslabljenimi ledvicami ali jetri podatki niso na voljo.

There are no data on the use of Xofigo at the same time as chemotherapy(other medicines used to kill cancer cells).
Na voljo ni podatkov o uporabi zdravila Xofigo sočasno s kemoterapijo(drugimi zdravili, ki se uporabljajo za uničevanje rakavih celic).

Information concerning data quality:- Advantages and disadvantages of the indicator: As there are no data on the situation in the past, the assessment of trends is not possible.
Informacije o kakovosti:- Prednosti in slabosti kazalca(z vidika podatkov): Ker ni podatkov o stanju v preteklosti ocena trendov ni mogoča.

There are no data regarding the efficacy of Panretin gel when applied to complicated lesions(e.g., when lymphoedema is present).
Ni podatkov oučinkovitosti zdravila Panretin gel pri nanosu na komplicirane lezije(npr.v prisotnosti limfedema).

Children and adolescents There are no data on the use of Bondronat in patients less than 18 years old.
Otroci in mladostniki O uporabi zdravila Bondronat pri bolnikih, mlajših od 18 let, ni podatkov.

There are no data on treatment with SIRTURO longer than 24 weeks within the clinical studies C208 and C209(see section 5.1).
V kliničnih študijah C208 in C209 ni podatkov o zdravljenju z zdravilom SIRTURO, ki bi trajalo več kot 24 tednov(glejte poglavje 5.1).

Children and adolescents There are no data available on the use of rosiglitazone in patients under 10 years of age.
Otroci in mladostniki Podatki o uporabi rosiglitazona pri bolnikih, mlajših od 10 let niso na voljo.

There are no data regarding the switch from a medicinal product of a different antiretroviral class to CELSENTRI in virologically suppressed patients.
Za virološko suprimirane bolnike ni podatkov o prehodu z zdravil iz druge protiretrovirusne skupine na zdravilo CELSENTRI.

Renal and hepatic function There are no data on the use of LITAK in patients with renal or hepatic impairment.
Delovanje ledvic in jeter O uporabi LITAKA pri bolnikih z okvarjenim delovanjem ledvic ali jeter ni podatkov.

There are no data in regards to the efficacy and safety of concomitant administration of HEXAVAC with Measles, Mumps and Rubella Virus Vaccine, live.
Trenutno ni podatkov o učinkovitosti in varnosti sočasnega cepljenja s HEXAVAC- om in živimi cepivi proti ošpicami, mumpsu in rdečkami.

Co-infection with hepatitis C or D: There are no data on the efficacy of tenofovir in patients co-infected with hepatitis C or D virus.
Sočasna okužba s hepatitisom C ali D: Podatkov o učinkovitosti tenofovirja pri bolnikih s sočasno okužbo z virusom hepatitisa C ali D ni.

There are no data with Pandemic influenza vaccine H5N1 MedImmune in children and adolescents younger than 18 years of age receiving salicylate therapy.
O Cepivu proti pandemski gripi H5N1 MedImmune ni podatkov pri otrocih in mladostnikih, mlajših od 18 let, ki prejemajo zdravljenje s salicilati.

Co-infection with hepatitis C or D: there are no data on the efficacy of entecavir in patients co-infected with hepatitis C or D virus.
Sočasna okužba z virusom hepatitisa C ali D: podatki o učinkovitosti entekavirja pri bolnikih s sočasno okužbo z virusom hepatitisa C ali D niso na voljo.

There are no data to support a steeper dose relationship for adverse reactions(myopathy, hepatotoxicity) for rosuvastatin, compared with other statins.
V primerjavi z drugimi statini ni podatkov, ki bi podpirali močnejšo povezavo neželenih reakcij(miopatija, hepatotoksičnost) z odmerkom rosuvastatina.

This is because there are no data on the use of Senshio in pregnant or pre-menopausal women or those who are breast-feeding.
Vzrok je v tem, ker ni podatkov o uporabi zdravila Senshio pri nosečnicah, ženskah pred menopavzo ali ženskah, ki dojijo.

There are no data available on the toxicity of Yttrium(90Y) chloride nor on its effects on reproduction in animals or its mutagenic or carcinogenic potential.
Na razpolago ni podatkov o toksičnosti itrijevega(90Y) klorida kot tudi ne o njegovih učinkih na reprodukcijo pri živalih ali njegovem mutagenem ali karcinogenem potencialu.

Children and adolescents There are no data available on the use of pioglitazone in patients under 18 years of age and therefore the use of Glubrava in this age group is not recommended.
O uporabi pioglitazona pri bolnikih, mlajših od 18 let, ni razpoložljivih podatkov in zato uporaba zdravila Glubrava pri tej starostni skupini ni priporočljiva.